3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
2
Phase 3
1
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Leukemia, Myeloid, Acute
1
Interventions
Cytarabine
89
Daunorubicin
45
Azacitidine
43
Idarubicin
27
venetoclax
26
fludarabine
26
Etoposide
25
Cyclophosphamide
25
Mitoxantrone
22
Decitabine
19
Busulfan
19
Methotrexate
16
Gemtuzumab
14
Granulocyte Colony-Stimulating Factor
12
Whole-Body Irradiation
10
Peripheral Blood Stem Cell Transplantation
10
Melphalan
10
gilteritinib
9
Filgrastim
9
fludarabine phosphate
8
Tacrolimus
8
Mycophenolic Acid
8
Cyclosporine
8
Tretinoin
7
Radiotherapy
7
Drug Therapy
7
Observation
6
Homoharringtonine
6
Antilymphocyte Serum
6
quizartinib
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Leukemia, Myeloid, Acute
×
vadastuximab talirine
×
Clear all
NCT02785900
2018-12-12
CASCADE
Seagen Inc.
Phase 3
Terminated
240 enrolled
20 charts